Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? / Roviello, G.; Buti, S.; Cattrini, C.; Mennitto, A.; Messina, C.; Airoldi, C.; Vannini, G.; Bersanelli, M.. - In: THERAPEUTIC ADVANCES IN UROLOGY. - ISSN 1756-2872. - 13:(2021), p. 17562872211029784. [10.1177/17562872211029784]

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Buti S.;Bersanelli M.
2021

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? / Roviello, G.; Buti, S.; Cattrini, C.; Mennitto, A.; Messina, C.; Airoldi, C.; Vannini, G.; Bersanelli, M.. - In: THERAPEUTIC ADVANCES IN UROLOGY. - ISSN 1756-2872. - 13:(2021), p. 17562872211029784. [10.1177/17562872211029784]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2913730
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact